Our team of scientists at Critical Outcome Technologies Inc. have spent several years evaluating our collective knowledge about cell signaling pathways in normal cells and how gene mutations alter these pathways in cancer cells. The underlying principle behind ROSALIND is that any hope of sustained remission is dependent on therapies that restore normal cell signaling to regulate cell division and apoptosis.
“We believe ROSALIND will empower physicians to make better individual patient treatment decisions based on an individual's cancer gene mutation profile. Leveraging the rapid advancements in genomic technologies and our understanding of the causal relationship between gene mutations and cell signaling abnormalities in cancer cells, ROSALIND is an exciting opportunity to make truly personalized cancer treatments a reality.”
- Dr. Wayne Danter.
The platform is driven by a dynamic, programmable computer simulation of how cell signaling pathways are altered by specific gene mutations that are associated with specific types of cancers. The resultant mutations determine new cancer cell signaling profiles and identify which pathways have been affected. The underlying patent pending technology produces a comprehensive mathematical model of cell signaling based on established relationships between individual cell signaling proteins. The platform is designed to help oncologists explore different agents or combinations that show the best promise of restoring normal cell signaling resulting in a possible remission. At this time, only physicians can order a ROSALIND assessment.
To learn more about ROSALIND, visit our website at www.ROSALINDonline.com. You can also follow @ROSALINDonline on Twitter or visit our Facebook Page.
A special thank you to Heisler Communications for helping with branding, developing the ROSALIND website, and helping build our social media presence.